TABLE OF CONTENTS
1 INTRODUCTION 24
1.1 OBJECTIVES OF THE STUDY 24
1.2 MARKET DEFINITION 24
1.3 OVERVIEW OF GLOBAL SCLERODERMA THERAPEUTICS MARKET 24
1.4 CURRENCY AND PRICING 27
1.5 LIMITATIONS 27
1.6 MARKETS COVERED 27
2 MARKET SEGMENTATION 30
2.1 MARKETS COVERED 30
2.2 GLOBAL SCLERODERMA THERAPEUTICS MARKET : GEOGRAPHICAL SCOPE 31
2.3 YEARS CONSIDERED FOR THE STUDY 32
2.4 CURRENCY AND PRICING 32
2.5 DBMR TRIPOD DATA VALIDATION MODEL 33
2.6 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 36
2.7 DBMR MARKET POSITION GRID 37
2.8 TIME LINE 38
2.9 MULTIVARIATE MODELLING 39
2.10 SECONDARY SOURCES 40
2.11 ASSUMPTIONS 40
3 MARKET OVERVIEW 41
3.1 DRIVERS 43
3.1.1 RISING CASES OF SCLERODERMA 43
3.1.2 INCREASING ACCESS TO MEDICAL INSURANCE IN THE U.S. 44
3.1.3 INCREASING MERGER AND ACQUISITIONS 44
3.2 RESTRAINTS 45
3.2.1 LACK OF CURATIVE TREATMENT 45
3.2.2 STRINGENT REGULATIONS 45
3.2.3 COUNTERFEIT PRODUCTS 46
3.3 OPPORTUNITY 47
3.3.1 UNMET PATIENT NEEDS IN SYSTEMIC SCLEROSIS 47
3.4 CHALLENGE 48
3.4.1 SIDE EFFECTS OF DRUGS 48
4 EXECUTIVE SUMMARY 49
5 PREMIUM INSIGHTS 53
6 PIPELINE PRODUCTS 56
7 EPIDEMIOLOGY 58
7.1 HISTORY OF SCLERODERMA: 58
7.2 RECENT INCIDENCE AND PREVALENCE: 59
7.3 CAUSE OF SCLERODERMA: 59
7.4 SYMPTOMS OF SCLERODERMA: 59
7.5 MANAGING SCLERODERMA: 59
8 GLOBAL SCLERODERMA THERAPEUTICS MARKET, BY TYPE 60
8.1 OVERVIEW 61
8.2 SYSTEMIC SCLERODERMA 62
8.2.1 LIMITED CUTANEOUS SYSTEMIC SCLEROSIS OR CREST SYNDROME 63
8.2.2 DIFFUSE SYSTEMIC SCLEROSIS 63
8.3 LOCALIZED SCLERODERMA 63
8.3.1 MORPHEA 64
8.3.2 LINEAR SCLERODERMA 64
9 GLOBAL SCLERODERMA THERAPEUTICS MARKET, BY TREATMENT TYPE 65
9.1 OVERVIEW 66
9.2 DRUG TREATMENT 67
9.2.1 DRUG TREATMENT, BY TYPE 68
9.2.1.1 ANTI-INFLAMMATORY DRUGS 68
9.2.1.2 IMMUNOSUPPRESSANTS 68
9.2.1.3 CORTICOSTEROIDS 68
9.2.1.4 PROTON PUMP INHIBITORS 68
9.2.1.5 CALCIUM CHANNEL BLOCKERS 69
9.2.1.6 ACE INHIBITORS 69
9.2.1.7 H2 BLOCKERS 69
9.2.1.8 PDE5 INHIBITORS 69
9.2.1.9 PROSTACYCLIN ANALOGUES 69
9.2.1.10 ENDOTHELIN RECEPTOR ANTAGONISTS 69
9.2.1.11 CHELATING AGENTS (EDATHAMIL DISODIUM) 69
9.2.1.12 OTHERS 69
9.2.2 DRUG TREATMENT, BY DISTRIBUTION CHANNEL 70
9.2.2.1 HOSPITAL PHARMACY 70
9.2.2.2 RETAIL PHARMACY 70
9.2.2.3 ONLINE PHARMACY 70
9.2.2.4 OTHERS 70
9.3 SURGICAL TREATMENT 71
9.4 THERAPY 71
9.4.1 ULTRAVIOLET LIGHT THERAPY 72
9.4.2 PHYSICAL THERAPY 72
9.4.3 OTHERS 72
10 GLOBAL SCLERODERMA THERAPEUTICS MARKET, BY END USER 73
10.1 OVERVIEW 74
10.2 HOSPITAL 75
10.3 SPECIALTY CLINICS 76
10.4 HOMECARE SETTINGS 76
10.5 OTHERS 77
11 GLOBAL SCLERODERMA THERAPEUTICS MARKET, BY GEOGRAPHY 78
11.1 OVERVIEW 79
11.2 NORTH AMERICA 84
11.2.1 U.S. 90
11.2.2 CANADA 92
11.2.3 MEXICO 95
11.3 EUROPE 98
11.3.1 U.K. 104
11.3.2 GERMANY 106
11.3.3 FRANCE 109
11.3.4 SPAIN 111
11.3.5 ITALY 114
11.3.6 NETHERLANDS 116
11.3.7 SWITZERLAND 119
11.3.8 BELGIUM 121
11.3.9 TURKEY 124
11.3.10 RUSSIA 126
11.3.11 REST OF EUROPE 128
11.4 ASIA-PACIFIC 129
11.4.1 JAPAN 135
11.4.2 CHINA 137
11.4.3 AUSTRALIA 140
11.4.4 SOUTH KOREA 142
11.4.5 INDIA 145
11.4.6 SINGAPORE 147
11.4.7 MALAYSIA 149
11.4.8 INDONESIA 152
11.4.9 THAILAND 155
11.4.10 PHILIPPINES 157
11.4.11 REST OF ASIA-PACIFIC 159
11.5 SOUTH AMERICA 160
11.5.1 BRAZIL 166
11.5.2 REST OF SOUTH AMERICA 168
11.6 MIDDLE EAST & AFRICA 169
11.6.1 SOUTH AFRICA 175
11.6.2 REST OF MIDDLE EAST & AFRICA 177
12 GLOBAL SCLERODERMA THERAPEUTICS MARKET, COMPANY LANDSCAPE 178
12.1 COMPANY SHARE ANALYSIS: GLOBAL 178
13 COMPANY PROFILES 179
13.1 ASTRAZENECA 179
13.1.1 COMPANY SNAPSHOT 179
13.1.2 REVENUE ANALYSIS 179
13.1.3 GEOGRAPHICAL PRESENCE 180
13.1.4 PRODUCT PORTFOLIO (PIPELINE) 180
13.1.5 RECENT DEVELOPMENTS 181
13.2 F. HOFFMANN-LA ROCHE LTD 182
13.2.1 COMPANY SNAPSHOT 182
13.2.2 REVENEUE ANALYSIS 182
13.2.3 GEOGRAPHICAL PRESENCE 183
13.2.4 PRODUCT PORTFOLIO 183
13.2.5 RECENT DEVELOPMENTS 184
13.3 NOVARTIS AG 185
13.3.1 COMPANY SNAPSHOT 185
13.3.2 REVENEUE ANALYSIS 185
13.3.3 GEOGRAPHICAL PRESENCE 186
13.3.4 PRODUCT PORTFOLIO 186
13.3.5 RECENT DEVELOPMENTS 188
13.4 PFIZER INC. 189
13.4.1 COMPANY SNAPSHOT 189
13.4.2 REVENEUE ANALYSIS 189
13.4.3 GEOGRAPHICAL PRESENCE 190
13.4.4 PRODUCT PORTFOLIO 190
13.4.5 RECENT DEVELOPMENTS 191
13.5 ABBVIE INC. 192
13.5.1 COMPANY SNAPSHOT 192
13.5.2 REVENEUE ANALYSIS 192
13.5.3 GEOGRAPHICAL PRESENCE 193
13.5.4 PRODUCT PORTFOLIO 193
13.5.5 RECENT DEVELOPMENTS 194
13.6 ACTIVE BIOTECH AB. 195
13.6.1 COMPANY OVERVIEW 195
13.6.2 REVENUE ANALYSIS 195
13.6.3 PRODUCT PORTFOLIO 196
13.6.4 RECENT DEVELOPMENT 196
13.7 ALLERGAN 197
13.7.1 COMPANY SNAPSHOT 197
13.7.2 REVENEUE ANALYSIS 197
13.7.3 GEOGRAPHICAL PRESENCE 198
13.7.4 PRODUCT PORTFOLIO 198
13.7.5 RECENT DEVELOPMENTS 199
13.8 ARGENTIS PHARMACEUTICALS, LLC. 200
13.8.1 COMPANY OVERVIEW 200
13.8.2 PRODUCT PORTFOLIO 200
13.8.3 RECENT DEVELOPMENTS 200
13.9 BRISTOL-MYERS SQUIBB COMPANY 201
13.9.1 COMPANY OVERVIEW 201
13.9.2 REVENUE ANALYSIS 201
13.9.3 GEOGRAPHICAL PRESENCE 202
13.9.4 PRODUCTS PORTFOLIO 202
13.9.5 RECENT DEVELOPMENTS 203
13.10 DAVAL INTERNATIONAL LIMITED 204
13.10.1 COMPANY SNAPSHOT 204
13.10.2 GEOGRAPHICAL PRESENCE 204
13.10.3 PRODUCT PORTFOLIO 205
13.10.4 RECENT DEVELOPMENT 205
13.11 GLAXOSMITHKLINE PLC. 206
13.11.1 COMPANY OVERVIEW 206
13.11.2 REVENUE ANALYSIS 206
13.11.3 GEOGRAPHICAL PRESENCE 207
13.11.4 PRODUCTS PORTFOLIO (PIPELINE DEVELOPMENT) 207
13.11.5 RECENT DEVELOPMENT 207
13.12 JOHNSON & JOHNSON SERVICES, INC. 208
13.12.1 COMPANY OVERVIEW 208
13.12.2 REVENUE ANALYSIS 208
13.12.3 GEOGRAPHICAL PRESENCE 209
13.12.4 PRODUCT PORTFOLIO (PIPELINE) 209
13.12.5 RECENT DEVELOPMENTS 209
13.13 SANOFI 210
13.13.1 COMPANY SNAPSHOT 210
13.13.2 REVENEUE ANALYSIS 210
13.13.3 GEOGRAPHICAL PRESENCE 211
13.13.4 PRODUCT PORTFOLIO 211
13.13.5 RECENT DEVELOPMENT 212
13.14 VIDA THERAPEUTICS INC. 213
13.14.1 COMPANY OVERVIEW 213
13.14.2 PRODUCT PORTFOLIO 213
13.14.3 RECENT DEVELOPMENTS 213
14 QUESTIONNAIRE 214
15 RELATED REPORTS 217